Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (301)	12/8/1998 8:17:00 AM
From: Ariella	Respond to of 1386

Interesting FDA article on brain injury: fda.gov

To: Ariella who wrote (301)	12/8/1998 8:47:00 AM
From: yosi s	Read Replies (1) \| Respond to of 1386

" Pharmos estimates that the worldwide opthalmic inflammation and allergy market is around $750 million." I have a problem with the definition of world wide. I wish they define it for me. is it Geographic world wide. is it Developed world wide. is it economically worthwhile. is it USA, Canada, Western Europe(How about former Eastern Europe),Japan, Brazil,Argentina, Australia, New Zealand. As you see those market potential are quite varied. What is more relevent to me is. 1. USA 2. LeTobra USA 4.. USA 100... USA Oh the other countries... I do not think Pharmos or BOL think that they are relevent Otherwise they would have APPLIED . And tried to get Alrex and Lotemax on the market.........